Tumor‐Associated Macrophage‐Derived CXCL1 Promotes Endometrial Cancer Progression Through the CXCR2/NF‐κB Pathway
Cancer Science · 2026
DOI: 10.1111/cas.70324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Ruiqi Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Receptors, Interleukin-8B, Chemokine CXCL1, Tumor-Associated Macrophages, NF-kappa B. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Advanced‐stage and metastatic endometrial cancer (EC) are characterized by markedly poor survival outcomes, necessitating a deeper understanding of the mechanisms driving disease advancement. Tumor‐associated macrophages (TAMs), particularly the M2 subtype, are instrumental in remodeling the tumor microenvironment and promoting EC proliferation, migration, and metastasis. However, the specific mediators responsible for TAM‐driven EC progression remain inadequately elucidated. In this study, we investigated the role of the C–X–C motif chemokine ligand 1 (CXCL1) and its receptor, chemokine receptor 2 (CXCR2), in TAM‐induced EC progression. CXCR2, as the primary receptor for CXCL1, activates the NF‐κB signaling pathway upon binding, thereby mediating the epithelial–mesenchymal transition process in EC cells and enhancing metastatic potential. This mechanism can be effectively inhibited by silencing CXCR2 or by employing the NF‐κB inhibitor BAY 11‐7082. Neutralizing CXCL1 markedly diminished the proliferative and migratory burdens imposed by TAMs on EC in subcutaneous xenograft EC models. Additionally, in EC tissue samples, CXCL1 and CXCR2 expression, as well as the extent of macrophage infiltration, exhibited a significant positive relationship with disease progression, suggesting an unfavorable prognosis. In conclusion, targeting the CXCL1/CXCR2 axis is a potential therapeutic approach for EC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
- Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
- Department of Pathology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
- Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
ORCID-Profile: Ruiqi Xia, Xianchao Kong
Förderung
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Xia, R., Qi, D., Ji, B., Dai, Y., & Kong, X. (2026). Tumor‐Associated Macrophage‐Derived CXCL1 Promotes Endometrial Cancer Progression Through the CXCR2/NF‐κB Pathway. Cancer Science. https://doi.org/10.1111/cas.70324
Vancouver
Xia R, Qi D, Ji B, Dai Y, Kong X. Tumor‐Associated Macrophage‐Derived CXCL1 Promotes Endometrial Cancer Progression Through the CXCR2/NF‐κB Pathway. Cancer Science. 2026. doi:10.1111/cas.70324
BibTeX
@article{Xia2026,
author = {Xia, Ruiqi and Qi, Dingtian and Ji, Boshu and Dai, Yisheng and Kong, Xianchao},
title = {Tumor‐Associated Macrophage‐Derived CXCL1 Promotes Endometrial Cancer Progression Through the CXCR2/NF‐κB Pathway},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70324}
}
EUVIMED